Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial
Conditions: Esophageal Cancer; Adenocarcinoma of the Esophagus Interventions: Drug: FLOT-CROSS or CROSS-FLOT Sponsors: Erasmus Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Hyper-Spectral Endoscopy for Detection of Early Neoplasia in Barrett's Oesophagus
Conditions: Endoscopy Interventions: Device: Hyper-Spectral Endoscopy Sponsors: University of Cambridge; University of Manchester Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Condition: Solid Tumor, KRAS Mutation Intervention: Drug: BI 3706674 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Conditions: Solid Tumor, KRAS Mutation Interventions: Drug: BI 3706674 Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Suprasorb ® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing
Conditions: Esophagus Injury; Rectal Lesion Intervention: Sponsors: Lohmann & Rauscher; CRI-The Clinical Research Institute GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2022 Category: Research Source Type: clinical trials
Use of routinely collected health data in randomised clinical trials: comparison of trial-specific death data in the BOSS trial with NHS Digital data
ConclusionNHS Digital death data is useful for calculating overall survival where trial-specific follow-up is only every 2 years from randomisation and the follow-up requires patient response. The cancer data was not a large enough sample to assess usability. We suggest that this assessment of registry data is done for more phase III RCTs and for more registry data to get a more complete picture of when RCHD would be useful in phase III RCT.Trial registrationISRCTN54190466 (BOSS) 1 Oct 2009. (Source: Trials)
Source: Trials - September 26, 2021 Category: Research Source Type: clinical trials
